Healthcare

The latest update provided a clearer picture of strengthening sales momentum, including a significant uplift in quarterly revenue, milestone monthly sales achievement, and continued progress in global commercial rollout across multiple markets.

PYC Therapeutics Ltd (ASX:PYC) has announced another development milestone within its Polycystic Kidney Disease program, with the biotechnology company confirming commencement of a Phase 1b Multiple Ascending Dose study for its investigational drug candidate PYC-003.

The market appeared to respond favourably to theLeadershipupdate, with investors focusing on Dr Speranza’s scientific, commercial andCapital Marketsbackground as the company advances development plans for its lead fibrosis treatment programme, VB0004.

Patagonia Lithium Ltd (ASX:PL3) shares closed unchanged at AUD 0.14 on 7 May 2026, with the stock holding steady despite the release of a favourable operational update tied to permitting progress and continued exploration activity at its flagship lithium projects in Argentina.

The latest announcement effectively builds on the governance reshuffle that emerged after four directors, including former CEO Dr Michael Baker, ceased their roles on 4 May 2026. While the earlier Appendix 3Z disclosures primarily documented the formal cessation of directors and their security interests, …

4DMedical Ltd (ASX: 4DX) has been one of the most extraordinary performers on the Australian share market over the past year, with its stock rising more than 1,031% before experiencing a sharp intraday correction of 10.6% in the latest session.

Arovella Therapeutics (ASX:ALA) rose 7.04% to AUD 0.076 on 7 May after the company announced it would present new pre-clinical data at the International Society for Cell & Gene Therapy 2026 Scientific Annual Meeting in Dublin.